Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Jazz Pharmaceuticals is to acquire Actio Biosciences in a deal that includes an $820m upfront payment and up to $500m in additional contingent payments.
Jazz Pharmaceuticals is to acquire Actio Biosciences in a deal that includes an $820m upfront payment and up to $500m in additional contingent payments.
Source: Pharmaceutical Technology